08:31 AM EDT, 09/23/2025 (MT Newswires) -- Solid Biosciences ( SLDB ) said Tuesday that it has signed a non-exclusive licensing and collaboration agreement with Kinea Bio to use Solid Biosciences' ( SLDB ) proprietary AAV-SLB101 to treat muscle tropism and reduced liver uptake.

Under the terms of the deal, Solid has granted Kinea Bio a non-exclusive worldwide license to use AAV-SLB101 to develop KNA-155 to treat dysferlinopathy, which is a type of muscular dystrophy. In exchange, Solid Biosciences ( SLDB ) will receive an upfront fee and is eligible for additional payments if certain milestones are met.

Financial terms were not disclosed.